Halberd Corporation (OTC: HALB) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and test subjects have been ordered. Parameter quantification and preliminary data gathering will begin as early as next week. The testing is being conducted for the development of a nasal spray to counteract the effects of head trauma.
Over the course of the past year, Halberd Corporation has been a company that has made considerable strides in its research and development part of the business.
This morning the company is in focus after if provided an update with regard to the current research that is going on at Mississippi State University. The company announced this morning that the researchers involved with the study at the Mississippi State University College of Veterinary Medicine got the approval with regards to its test protocol. Additionally, the test subjects had also been ordered. The preliminary data-gathering work as well as the parameter qualifications would commence early next week.
It has been cited in the medical literature that there is a connection between some of the excess neurotransmitters and some neurodegenerative diseases. The study from Halberd is going to look for positive outcomes in such cases by minimizing the excess neurotransmitters through the use of its triple-action nasal spray, for which a patent is still pending.
The nasal spray in question contains a number of ingredients that help in the prevention of inflammation and swelling. It also limited the generation of excess neurotransmitters and also reduces hypermetabolism. It should be noted that the nasal spray is an extension of the company’s unique extracorporeal methodology which has proven its effectiveness in preventing a range of health conditions. The methodology mainly goes for a preventive approach and also offers more intellectual property opportunities to Halberd.